// App-Quantinova.ai

POS0446 (2021) : FILGOTINIB-TREATED RHEUMATOID ARTHRITIS PATIENTS WITH HIGH BASELINE NEUTROPHIL-TO-LYMPHOCYTE RATIO SHOW BETTER CLINICAL RESPONSE RATES AND PATIENT-REPORTED OUTCOMES

Researchers

Presenter

  • P. C. Taylor

Principal Investigators

  • B. Downie

  • S. Kim

  • R. Hawtin

  • R. Moots

  • T. Takeuchi

Medical Centers

  • University of Oxford, Botnar Research Centre, Nuffield Dept Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

  • 1.Gilead Science Inc, Foster City, United States of America

  • Edge Hill University, Faculty of Health, Social Care and Medicine, Ormskirk, United Kingdom

  • The Jikei University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Department of Endoscopy, Tokyo, Japan

Locations

  • United Kingdom

  • United States

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Neutrophil lymphocyte ratio

Drug/Treatment

  • Methotrexate

  • Filgotinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02886728

  • NCT02889796

  • NCT02873936

Sponsors

  • Celgene

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved